Ryuji Ueno

R-Tech Ueno Ltd. engages in the research and development, manufacture and sale of pharmaceutical products. It operates through the following business divisions: New Pharmaceutical Research and Development, Pharmaceutical Manufacture and Sale, and Pharmaceutical Development Support and Contract Manufacturing Services. The New Pharmaceutical Research and Development business provides development for unmet medical needs area, orphan drug area, and anti-aging area. The Pharmaceutical Manufacture and Sale business handles the manufacture and sale of Rescula Eye Drops for glaucoma and ocular hypertension. The Pharmaceutical Development Support and Contract Manufacturing Services business covers the manufacture and sale of AMITIZA capsules for chronic idiopathic constipation. It also accepts contract manufacturing of eye drops, liquid drugs and liquid-filled hard capsules. The company was founded by Ryuji Ueno and Sachiko Kuno in September 1989 and is headquartered in Tokyo, Japan.

S&R Technology Holdings LLC provide support to global entrepreneurs and new businesses. It offers managing and growing global ventures. The company was founded by Sachiko Kuno and Ryuji Ueno in 1999 and is headquartered in Bethesda, MD.

Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development, identification, acquisition, and delivery of innovative pharmaceutical products. The company was founded by Ryuji Ueno and Sachiko Kuno on December 5, 1996 and is headquartered in Bethesda, MD.

Part of Mallinckrodt Plc, Sucampo GmbH is a Swiss company that manufactures and distributes pharmaceuticals and health care products. The company is based in Zug, Switzerland. The company was founded by Ryuji Ueno, Sachiko Kuno. Sucampo was acquired by Sucampo Pharmaceuticals LLC, part of Mallinckrodt Plc from February 14, 2018 on December 29, 2010 for $120 million.

The S&R Foundation provides support for artists and scientists involved in the arts, sciences, and social entrepreneurship, especially those furthering international and cultural collaboration. The company was founded by Sachiko Kuno and Ryuji Euno in 2000 and is headquartered in Washington, DC.

VLP Therapeutics LLC operates as a biopharmaceutical company. The firm focuses on developing preventative and therapeutic vaccines, as well as next generation targeted antibody agents to treat cancer and infectious diseases, such as malaria, dengue fever, zika virus-based diseases, and autoimmune. The company was founded by Wataru Akahata, Ryuji Ueno, Sachiko Kuno, Kei S. Tolliver and Misako Nakata in 2012 and is headquartered in Gaithersburg, MD.